Immune checkpoint inhibitors and myocarditis in advanced non-small cell lung cancer: a nationwide cohort study.

ABSTRACT:

Objective

Evidence suggests immune checkpoint inhibitor (ICI) can increase the risk of myocarditis. We investigated it in a large national cohort in China.

Methods

Patients with stage IIIB-IV non-small cell lung cancer (NSCLC) using data from China's National Anti-Tumor Drug Surveillance System between January 2013 and December 2021. Exposure density sampling was applied to control for immortal time bias. Multivariate Cox regression with time-dependent exposures was used to examine the association between ICI therapy and the incidence of myocarditis while controlling for confounders.

Results

55,219 patients were included. The median age was 61 years, and 62% were males. At one-year follow-up (median 335 days), there were 26 cases of myocarditis among ICI users and 28

SUBMITTER: Li FX 

PROVIDER: S-EPMC11956456 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature